The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Parapres     1- cyclohexyloxycarbonyloxyethyl 2-ethoxy-3...

Synonyms: Atacand, Racanda, Kenzen, ATACAND HCT, CHEMBL1014, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Candesartan cilexetil


High impact information on Candesartan cilexetil

  • Tumor growth was also reduced in WT mice treated with TCV-116, a selective blocker of AT1 receptor [4].
  • TCV-116 (10, a selective nonpeptide AT1 receptor antagonist, or vehicle was administered orally to rats from 1 day before to 14 days after balloon injury [5].
  • Immunohistological studies indicated that TCV-116 decreased not only the intimal thickening but also the amount of these extracellular matrix proteins in the intima [5].
  • In the in vitro study, neonatal rat cardiomyocytes were cultured on deformable silicone dishes and mechanically stretched with or without pretreatment of CV-11974 (an active metabolite of TCV-116), and [3H]phenylalanine incorporation, activity of mitogen-activated protein (MAP) kinase, and c-fos mRNA expression were analyzed [1].
  • Further evaluation of the effect of TCV-116 revealed that SHR treated with a low dose of TCV-116 (1 mg/kg per day) showed a decrease in left ventricular mass with only a little decrease in blood pressure and that the incidence of VT/Vf was reduced in association with the degree of regression of LVH [6].

Chemical compound and disease context of Candesartan cilexetil


Biological context of Candesartan cilexetil


Anatomical context of Candesartan cilexetil


Associations of Candesartan cilexetil with other chemical compounds


Gene context of Candesartan cilexetil


Analytical, diagnostic and therapeutic context of Candesartan cilexetil


  1. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Kojima, M., Shiojima, I., Yamazaki, T., Komuro, I., Zou, Z., Wang, Y., Mizuno, T., Ueki, K., Tobe, K., Kadowaki, T. Circulation (1994) [Pubmed]
  2. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Nagisa, Y., Shintani, A., Nakagawa, S. Diabetologia (2001) [Pubmed]
  3. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. Tsutamoto, T., Wada, A., Maeda, K., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Sawaki, M., Fujii, M., Matsumoto, T., Kinoshita, M. J. Am. Coll. Cardiol. (2000) [Pubmed]
  4. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. Egami, K., Murohara, T., Shimada, T., Sasaki, K., Shintani, S., Sugaya, T., Ishii, M., Akagi, T., Ikeda, H., Matsuishi, T., Imaizumi, T. J. Clin. Invest. (2003) [Pubmed]
  5. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Kim, S., Kawamura, M., Wanibuchi, H., Ohta, K., Hamaguchi, A., Omura, T., Yukimura, T., Miura, K., Iwao, H. Circulation (1995) [Pubmed]
  6. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Kohya, T., Yokoshiki, H., Tohse, N., Kanno, M., Nakaya, H., Saito, H., Kitabatake, A. Circ. Res. (1995) [Pubmed]
  7. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. Rosei, E.A., Rizzoni, D., Muiesan, M.L., Sleiman, I., Salvetti, M., Monteduro, C., Porteri, E. J. Hypertens. (2005) [Pubmed]
  8. The role of blood pressure lowering before and after stroke. Donnan, G.A., Davis, S.M., Thrift, A. Curr. Opin. Neurol. (2003) [Pubmed]
  9. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. Asmar, R., Lacourcière, Y. J. Hypertens. (2000) [Pubmed]
  10. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Melian, E.B., Jarvis, B. Drugs (2002) [Pubmed]
  11. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. Paull, J.R., Widdop, R.E. J. Hypertens. (2001) [Pubmed]
  12. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Kim, S., Ohta, K., Hamaguchi, A., Omura, T., Yukimura, T., Miura, K., Inada, Y., Wada, T., Ishimura, Y., Chatani, F. Hypertension (1994) [Pubmed]
  13. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Ghiadoni, L., Virdis, A., Magagna, A., Taddei, S., Salvetti, A. Hypertension (2000) [Pubmed]
  14. Improvement in baroreflex function by an oral angiotensin receptor antagonist in rats with myocardial infarction. Nishizawa, M., Kumagai, H., Ichikawa, M., Oshima, N., Suzuki, H., Saruta, T. Hypertension (1997) [Pubmed]
  15. Type 1 angiotensin II receptor antagonism reduces antigen-induced airway reactions. Myou, S., Fujimura, M., Kurashima, K., Tachibana, H., Watanabe, K., Hirose, T. Am. J. Respir. Crit. Care Med. (2000) [Pubmed]
  16. Candesartan cilexetil: an update of its use in essential hypertension. Easthope, S.E., Jarvis, B. Drugs (2002) [Pubmed]
  17. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Otsuka, M., Takahashi, H., Shiratori, M., Chiba, H., Abe, S. Thorax (2004) [Pubmed]
  18. Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. Tsuchihashi, T., Kagiyama, S., Matsumura, K., Abe, I., Fujishima, M. J. Hypertens. (1999) [Pubmed]
  19. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. Kawamura, M., Terashita, Z., Okuda, H., Imura, Y., Shino, A., Nakao, M., Nishikawa, K. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  20. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery. Tazawa, S., Nakane, T., Chiba, S. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
  21. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. Hanatani, A., Yoshiyama, M., Kim, S., Omura, T., Toda, I., Akioka, K., Teragaki, M., Takeuchi, K., Iwao, H., Takeda, T. J. Mol. Cell. Cardiol. (1995) [Pubmed]
  22. Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. Muramatsu, M., Katada, J., Hayashi, I., Majima, M. J. Biol. Chem. (2000) [Pubmed]
  23. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Delacrétaz, E., Nussberger, J., Biollaz, J., Waeber, B., Brunner, H.R. Hypertension (1995) [Pubmed]
  24. Angiotensin receptor gene expression in candesartan mediated neuroprotection. Lu, Q., Zhu, Y.Z., Wong, P.T. Neuroreport (2004) [Pubmed]
  25. Role of angiotensin II, endothelin-1, and nitric oxide in HgCl2-induced acute renal failure. Yanagisawa, H., Nodera, M., Umemori, Y., Shimoguchi, Y., Wada, O. Toxicol. Appl. Pharmacol. (1998) [Pubmed]
  26. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Fujita, M., Hayashi, I., Yamashina, S., Itoman, M., Majima, M. Biochem. Biophys. Res. Commun. (2002) [Pubmed]
  27. Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. Kitami, Y., Okura, T., Marumoto, K., Wakamiya, R., Hiwada, K. Biochem. Biophys. Res. Commun. (1992) [Pubmed]
  28. Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats. Hara, K., Kobayashi, N., Nakano, S., Mori, Y., Tsubokou, Y., Matsuoka, H. Hypertens. Res. (2001) [Pubmed]
  29. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Furukawa, Y., Matsumori, A., Hirozane, T., Sasayama, S. Circulation (1996) [Pubmed]
  30. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats. Inscho, E.W., Imig, J.D., Deichmann, P.C., Cook, A.K. J. Am. Soc. Nephrol. (1999) [Pubmed]
  31. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Rossing, K., Christensen, P.K., Jensen, B.R., Parving, H.H. Diabetes Care (2002) [Pubmed]
  32. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Omoto, K., Tanabe, K., Tokumoto, T., Shimmura, H., Ishida, H., Toma, H. Transplantation (2003) [Pubmed]
WikiGenes - Universities